Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

Core Insights - Spyre Therapeutics, Inc. has successfully closed an underwritten public offering of 17,094,594 shares of common stock at a price of $18.50 per share, raising approximately $316.2 million in gross proceeds before expenses [1] Company Overview - Spyre Therapeutics is a clinical-stage biotechnology company focused on developing next-generation treatments for inflammatory bowel disease (IBD) and other immune-mediated diseases through advanced antibody engineering and therapeutic combinations [5]